东宝生物(300239) - 2022 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2022 was ¥943,396,998.69, representing a 54.11% increase compared to ¥612,165,671.91 in 2021[25]. - Net profit attributable to shareholders reached ¥109,437,321.14, a significant increase of 199.96% from ¥36,484,130.69 in the previous year[25]. - The net profit after deducting non-recurring gains and losses was ¥100,942,931.19, up 274.97% from ¥26,920,029.36 in 2021[25]. - Cash flow from operating activities increased by 279.25% to ¥195,317,536.56, compared to ¥51,501,086.21 in 2021[25]. - Basic and diluted earnings per share rose to ¥0.1844, reflecting an increase of 185.01% from ¥0.0647 in 2021[25]. - Total assets at the end of 2022 were ¥2,308,113,622.60, a 9.27% increase from ¥2,112,240,503.24 at the end of 2021[25]. - The company's net assets attributable to shareholders increased by 7.44% to ¥1,528,509,817.66 from ¥1,422,692,834.57 in 2021[25]. - In 2022, the company achieved a revenue of CNY 943,396,998.69, representing a year-on-year growth of 54.11%[67]. - The total profit for the year was CNY 131,647,053.37, which is an increase of 216.91% compared to the previous year[67]. - The net profit attributable to the parent company was CNY 109,437,321.14, marking a growth of 199.96% year-on-year[67]. Market Expansion and Strategy - The company is exploring market expansion opportunities, particularly in the health food sector, which is expected to grow significantly[15]. - The management has indicated a positive outlook for future performance, driven by increased demand for health-related products[15]. - The company is considering strategic partnerships and acquisitions to enhance its market position and product offerings[15]. - The company is focusing on expanding its market share in the health and nutrition sectors, which are expected to see further concentration and growth[48]. - The company is actively developing OEM business and providing guidance in market development and packaging design to ensure stable cooperation with clients[86]. - The company plans to implement an integrated production layout to improve capacity utilization and product quality while controlling production costs, focusing on projects like the new hollow capsule industrialization project[162]. - The company aims to enhance its market share in the TO C segment and strengthen its brand influence while optimizing internal operations to improve asset utilization efficiency[156]. - The company intends to expand its TO B product market, particularly in specialized gelatin and collagen protein, leveraging existing customer relationships and enhancing service levels[158]. Research and Development - The company is actively involved in research and development, particularly in the field of collagen production, with plans for a new 2,000-ton project[15]. - The company has established key laboratories and research centers, enhancing its production capabilities for collagen proteins and gelatin, achieving import substitution in the field of gelatin[73]. - The company has developed a diverse range of consumer products under the "Collagen+" series, catering to various health needs across different age groups[55]. - Research and development expenses increased by 99.05% to ¥25,831,595.08, primarily due to the consolidation of the subsidiary Yiqing Bio[106]. - R&D investment amounted to ¥39,472,620.22 in 2022, representing 4.18% of operating revenue, up from 3.93% in 2021[108]. - The company has a strong focus on innovation, with a robust patent portfolio supporting its product development and market expansion strategies[74]. Production Capacity and Operations - The company is focused on expanding its production capacity, with a project to increase gelatin production from 3,500 tons to 7,000 tons annually[15]. - The company has an annual production capacity of 13,500 tons of gelatin and 24 billion capsules, leading the industry in scale[52]. - The subsidiary Yiqing Bio is advancing the "New Intelligent Industrialization Project for Hollow Capsules," aiming for an annual production capacity of nearly 70 billion capsules upon completion[52]. - The company is currently implementing a project to expand the production capacity of new intelligent hollow capsules to 30 billion capsules annually[69]. - The company has established a comprehensive production quality management system, certified by FSSC22000 and ISO standards[70]. Governance and Compliance - The company has established a robust governance structure, ensuring compliance with regulatory requirements and enhancing shareholder value[5]. - The board of directors consists of 7 members, including 3 independent directors, and operates under various committees to ensure compliance and effective governance[178]. - The company has implemented a performance evaluation and incentive mechanism, including an employee stock ownership plan to enhance cohesion and growth[178]. - The company maintains transparent communication with investors through various channels, ensuring timely and accurate information disclosure[179]. - There are no significant discrepancies between the company's governance practices and the regulations set forth by the China Securities Regulatory Commission[179]. Risks and Challenges - The company has outlined potential risks and corresponding countermeasures in the section discussing future development prospects[5]. - The company acknowledges the risk of intensified market competition and aims to enhance product innovation and service capabilities to maintain market share[167]. - The company is addressing the risk of raw material price fluctuations by conducting market research and implementing differentiated procurement strategies to stabilize costs[168]. - Regulatory risks are increasing in the pharmaceutical and health food sectors, necessitating enhanced market and policy research to adapt to new regulations[172]. Sustainability and Social Responsibility - The management team emphasized a commitment to sustainability, with plans to implement eco-friendly practices across all operations by the end of 2023[195]. - The company is committed to continuous improvement in its production processes and environmental sustainability, as evidenced by its new wastewater treatment systems[76]. Financial Management and Investments - The company raised a total of RMB 407,281,700.00 in funds, with a net amount of RMB 396,693,480.24 after deducting issuance-related expenses of RMB 10,588,219.76[139]. - The company has long-term borrowings of CNY 152,000,000.00, which constitutes 6.59% of total liabilities, indicating a new financing strategy[117]. - The company reported an investment amount of ¥155,905,672.96 in 2022, a decrease of 53.70% compared to the previous year's investment of ¥336,730,348.40[126]. - The company has not engaged in any securities or derivative investments during the reporting period[136][137].